Engineered Mesenchymal Stem Cell-NK Cell Complexes for Spatially Targeted and Functionally Revitalized Cancer Immunotherapy.
Zhang Q., Yin B., Sabier M., Yang Y., Wu M., Zhao Z.
Animal Study, published in Adv Sci (Weinh) (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Adv Sci (Weinh) (2025)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40827682
- PMCID
- PMC13292232
- DOI
- 10.1002/advs.202509638
- Citations
- 1
Abstract (original English)
Natural killer (NK) cells represent a powerful immunotherapeutic strategy due to their intrinsic cytotoxicity and ability to target tumor cells independently of antigen presentation. However, their clinical efficacy against solid tumors is limited by poor tumor infiltration and impaired functionality within the immunosuppressive microenvironment. Here, a genetically engineered cell-cell complex delivery system comprising NK cells conjugated to IL-15 expressing adipose-derived mesenchymal stem cells (SCs) is developed. By exploiting SCs' intrinsic tumor-tropic properties and engineering them to consistently express interleukin-15 (IL-15) via lipid nanoparticle-mediated mRNA transfection, the SC-NK cell complexes exhibit markedly improved tumor localization and sustained cytokine-mediated functional enhancement. Utilizing bioorthogonal click chemistry for precise conjugation, the approach effectively enhances NK cell infiltration and revitalizes their cytotoxic activity in both orthotopic murine lung cancer and patient-derived xenograft ovarian cancer models. Furthermore, increased responsiveness of the cell-cell complexes to Galectin-9 blockade therapy is identified, leading to the reversal of NK cell dysfunction and significantly augmented antitumor efficacy. Collectively, the engineered SC-assisted delivery system holds potential for overcoming the limitations of NK cell thera
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.